Spirit Scientific (7790) showcased its high-concentration PLT services and new platelet-derived cellular signal factors lyophilization services at the 2025 Taiwan Dermatological Association Spring Academic Conference (AMWC Asia-TDAC 2025) held in Taipei. The company also announced its recent receipt of the prestigious “Golden Peak Award,” earning “Top Ten Outstanding Products” and “Top Ten Outstanding Entrepreneurship Models.”
The conference, co-organized by the Taiwan Dermatological Association (TDA) and the Taiwan Society for Dermatologic and Cosmetic Surgery (TSDAS), is a major event in East Asia focusing on cutting-edge advancements in cosmetic medicine, dermatology, and anti-aging.
During the conference, Spirit Scientific biotech hosted a satellite symposium moderated by Dr. Cheng-Hsien Lin, director of Lin Dermatology Clinic. Dr. Chia-Mao Kao, director of Qi Yue Mei Yi Dermatology Clinic, presented on cellular signal factors mechanisms in promoting hair growth and shared clinical experiences using autologous platelet-derived cellular signal factors lyophilization for hair restoration. Spirit Scientific biotech launched its “Autologous Platelet-Derived cellular signal factors Lyophilization Preparation Service” in February, which processes autologous blood in a GTP-compliant laboratory under sterile conditions.
Spirit Scientific emphasizes adherence to ISEV’s MISEV2023 guidelines for exosome quality control, including quantity, size, surface markers, and purity. The final product undergoes gamma irradiation sterilization, 9 safety tests, and provides a growth factor concentration report for customized treatment dosages.
Additionally, Spirit Scientific biotech’s innovative high-concentration PLT preparation service won “Top Ten Outstanding Products,” and its founder and chairman, Dr. Dao-Long Lin, received the “Top Ten Outstanding Entrepreneurship Model” award at the 23rd Golden Peak Awards. This award recognizes innovative enterprises, with Spirit Scientific biotech standing out among over 500 competitors due to its advancements in regenerative medicine technology and service models.
Source: https://news.gbimonthly.com/tw/article/show.php?num=76600
